In conclusion, better understanding the integrative role that IL-1α and IL-1β play in animal experimental models and in cancer patients, together with “IL-1 mapping” at tumor sites, as indicated above, should pave the way for safe and efficient application of anti-IL-1 therapies at the bedside for cancer patients. The gene discussed is IL1B; the disease is neoplasm.